Switch theme
Sign up to access all valuation multiples
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
2000
1.3K+
LTM Revenue $489M
LTM EBITDA $36.8M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AtriCure has a last 12-month revenue (LTM) of $489M and a last 12-month EBITDA of $36.8M.
In the most recent fiscal year, AtriCure achieved revenue of $465M and an EBITDA of -$18.5M.
AtriCure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AtriCure valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $489M | XXX | $465M | XXX | XXX | XXX |
| Gross Profit | $366M | XXX | $348M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $36.8M | XXX | -$18.5M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | -4% | XXX | XXX | XXX |
| EBIT | -$33.5M | XXX | -$40.0M | XXX | XXX | XXX |
| EBIT Margin | -7% | XXX | -9% | XXX | XXX | XXX |
| Net Profit | -$37.7M | XXX | -$44.7M | XXX | XXX | XXX |
| Net Margin | -8% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AtriCure's stock price is $35.
AtriCure has current market cap of $1.7B, and EV of $1.7B.
See AtriCure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.7B | XXX | XXX | XXX | XXX | $-0.79 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AtriCure has market cap of $1.7B and EV of $1.7B.
AtriCure's trades at 3.6x EV/Revenue multiple, and -91.1x EV/EBITDA.
Equity research analysts estimate AtriCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AtriCure has a P/E ratio of -45.4x.
See valuation multiples for AtriCure and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 45.9x | XXX | -91.1x | XXX | XXX | XXX |
| EV/EBIT | -50.5x | XXX | -42.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -45.4x | XXX | -38.3x | XXX | XXX | XXX |
| EV/FCF | 521.1x | XXX | -150.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAtriCure's last 12 month revenue growth is 12%
AtriCure's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
AtriCure's rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AtriCure's rule of X is 39% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AtriCure and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | -4% | XXX | XXX | XXX |
| EBITDA Growth | 36% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 10% | XXX | 8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AtriCure acquired XXX companies to date.
Last acquisition by AtriCure was XXXXXXXX, XXXXX XXXXX XXXXXX . AtriCure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AtriCure founded? | AtriCure was founded in 2000. |
| Where is AtriCure headquartered? | AtriCure is headquartered in United States of America. |
| How many employees does AtriCure have? | As of today, AtriCure has 1.3K+ employees. |
| Who is the CEO of AtriCure? | AtriCure's CEO is Mr. Michael H. Carrel. |
| Is AtriCure publicy listed? | Yes, AtriCure is a public company listed on NAS. |
| What is the stock symbol of AtriCure? | AtriCure trades under ATRC ticker. |
| When did AtriCure go public? | AtriCure went public in 2005. |
| Who are competitors of AtriCure? | Similar companies to AtriCure include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of AtriCure? | AtriCure's current market cap is $1.7B |
| What is the current revenue of AtriCure? | AtriCure's last 12 months revenue is $489M. |
| What is the current revenue growth of AtriCure? | AtriCure revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of AtriCure? | Current revenue multiple of AtriCure is 3.5x. |
| Is AtriCure profitable? | Yes, AtriCure is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AtriCure? | AtriCure's last 12 months EBITDA is $36.8M. |
| What is AtriCure's EBITDA margin? | AtriCure's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of AtriCure? | Current EBITDA multiple of AtriCure is 45.9x. |
| What is the current FCF of AtriCure? | AtriCure's last 12 months FCF is $3.2M. |
| What is AtriCure's FCF margin? | AtriCure's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of AtriCure? | Current FCF multiple of AtriCure is 521.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
